 |
Samuel L. Stanley Jr., M.D.
|
|
Samuel L. Stanley Jr., M.D. Vice Chancellor for Research Professor of Medicine, Professor of Molecular Microbiology, Director, Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Office Location: 7244 McDonnell Pediatric Research Building Dr. Stanley joined the Division of Infectious Diseases in 1987. He received his M.D. degree from Harvard Medical School, and completed his internal medicine training at the Massachusetts General Hospital in Boston. Dr. Stanley trained in the infectious diseases program at Washington University School of Medicine, and joined the faculty after completing a post-doctoral fellowship in immunology at Washington University School of Medicine. His current clinical interests include biodefense, vaccines, tropical diseases and travelers' health. The major focus of his research is on enteric pathogens and their interaction with the host innate immune system. Research Interests "My primary research interests center on the nature of the host response to enteric pathogens. My laboratory studies a number of gut pathogens, including the extracellular protozoan parasite, Entamoeba histolytica, the intracellular protozoan Cryptosporidium parvum, the extracellular bacteria Bacillus cereus, and the intracellular bacteria, Shigella flexneri, focusing on their interactions with intestinal epithelial cells and host defenses. A key to our research was the development of a severe combined immunodeficient /human intestinal xenograft (SCID-HU-INT) mouse model, allowing us to directly study the interactions of these pathogens with human intestine. We are using a variety of techniques, including microarray analysis to ask fundamental questions about how pathogens injure the gut, how the inflammatory response contributes to that injury, and whether the gut responses to pathogens is specific for a given organism, or a stereotypic response to injury. We are also involved in developing new drugs for anaerobic or facultatively anaerobic organisms by targeting a key enzyme in their metabolic pathway." Finally, a new interest in the lab is biodefense, specifically genetic factors that may pre-dispose individuals to adverse events from vaccines.
Division of Infectious Diseases
|
